• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    REPAY Appoints New Chief Financial Officer

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    $MRK
    Real Estate
    Real Estate
    Real Estate
    Real Estate
    Get the next $CNDT alert in real time by email

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025.

    "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO.

    Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT) ("Conduent"). He previously served as Conduent's Global Head of Strategy, Corporate Development and Advisor to CEO. Prior to Conduent, Rob spent seven years at Fiserv, Inc. (NYSE:FI) holding positions as Senior Vice President, General Manager, and CFO across several divisions. Prior to Fiserv, he was the Global Head of FP&A and Investor Relations at Integra Lifesciences, Inc. (NASDAQ:IART). He previously held various finance, accounting, and strategy roles at Firmenich, Inc, Bristol-Myers Squibb Co. (NYSE:NMY), and Merck & Co Inc. (NYSE:MRK). Rob began his career as an auditor for KPMG LLP, and he earned his MBA and bachelor's degree in accounting from Rider University.

    "With Rob's appointment, interim CFO Thomas Sullivan will return to his role as Chief Accounting Officer. We are extremely grateful for Thomas's help in managing the finance organization over the past several months and the entire REPAY team for supporting the company through the CFO transition," said John Morris.

    About REPAY

    REPAY provides integrated payment processing solutions to verticals that have specific transaction processing needs. REPAY's proprietary, integrated payment technology platform reduces the complexity of electronic payments for clients, while enhancing the overall experience for consumers and businesses.

    Forward-Looking Statements

    This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about REPAY's expectations with respect to the announced leadership changes. Such forward-looking statements are based upon the current beliefs and expectations of REPAY's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond REPAY's control, including, without limitation, the factors described in REPAY's reports filed with the U.S. Securities and Exchange Commission. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. All information set forth herein speaks only as of the date hereof in the case of information about REPAY or the date of such information in the case of information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250811411111/en/

    Investor Relations for REPAY:

    [email protected]



    Media Relations for REPAY:

    Kristen Hoyman

    [email protected]

    Get the next $CNDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNDT
    $FI
    $IART
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    9/17/2025$90.00Buy → Hold
    Berenberg
    Fiserv Inc.
    $FI
    7/21/2025Sell → Neutral
    Monness Crespi & Hardt
    Fiserv Inc.
    $FI
    7/17/2025Buy
    Deutsche Bank
    Fiserv Inc.
    $FI
    6/2/2025$181.00Buy
    Truist
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    Fiserv Inc.
    $FI
    4/17/2025$150.00Neutral → Sell
    Redburn Atlantic
    Fiserv Inc.
    $FI
    4/9/2025$145.00Neutral → Sell
    Monness Crespi & Hardt
    More analyst ratings

    $CNDT
    $FI
    $IART
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Yarkoni Charlotte

    4 - FISERV INC (0000798354) (Issuer)

    10/2/25 4:43:15 PM ET
    $FI
    Real Estate

    SEC Form 4 filed by Director Simons Doyle

    4 - FISERV INC (0000798354) (Issuer)

    10/2/25 4:41:17 PM ET
    $FI
    Real Estate

    SEC Form 4 filed by Director Mamilli Wafaa

    4 - FISERV INC (0000798354) (Issuer)

    10/2/25 4:40:28 PM ET
    $FI
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Merck downgraded by Berenberg with a new price target

    Berenberg downgraded Merck from Buy to Hold and set a new price target of $90.00

    9/17/25 7:56:07 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fiserv upgraded by Monness Crespi & Hardt

    Monness Crespi & Hardt upgraded Fiserv from Sell to Neutral

    7/21/25 8:07:58 AM ET
    $FI
    Real Estate

    Deutsche Bank resumed coverage on Fiserv

    Deutsche Bank resumed coverage of Fiserv with a rating of Buy

    7/17/25 9:24:17 AM ET
    $FI
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    SEC Filings

    View All

    SEC Form S-8 filed by Repay Holdings Corporation

    S-8 - Repay Holdings Corp (0001720592) (Filer)

    9/26/25 5:20:02 PM ET
    $RPAY
    Real Estate

    Merck & Company Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Merck & Co., Inc. (0000310158) (Filer)

    9/9/25 4:33:09 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Merck & Company Inc.

    424B5 - Merck & Co., Inc. (0000310158) (Filer)

    9/4/25 4:15:44 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Agadi Harshavardhan V bought $281,000 worth of shares (100,000 units at $2.81) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    6/20/25 11:34:48 AM ET
    $CNDT
    Real Estate

    Amendment: President and CEO Skelton Clifford bought $101,700 worth of shares (45,000 units at $2.26), increasing direct ownership by 1% to 4,383,552 units (SEC Form 4)

    4/A - CONDUENT Inc (0001677703) (Issuer)

    5/19/25 9:56:21 PM ET
    $CNDT
    Real Estate

    President Alias Shaler bought $490 worth of shares (118 units at $4.15) (SEC Form 4)

    4 - Repay Holdings Corp (0001720592) (Issuer)

    5/16/25 5:00:19 PM ET
    $RPAY
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fiserv Small Business Index Holds Steady As Consumers Remain Cautious Through September

    Fiserv Small Business Index remains at 148 Year-over-year sales grew +2.3% Fiserv, Inc. (NYSE:FI), a leading global provider of payments and financial services technology, has published the Fiserv Small Business Index for September 2025, with the seasonally adjusted Index holding steady at 148 for a third consecutive month. Year-over-year sales (+2.3%) and transactions (+2.3%) grew steadily, and average ticket sizes (+0.1%) increased modestly compared to 2024. Month-over-month sales (+0.1%) and transactions (+0.3%) saw small increases; average ticket sizes fell (-0.2%) slightly compared to August. "Pragmatism continued to guide consumer spending in September, with discretionary pur

    10/3/25 8:00:00 AM ET
    $FI
    Real Estate

    HEALTH CANADA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-release Injectable Suspension) from Merck Animal Health

    KIRKLAND, QC, Oct. 2, 2025 /CNW/ -- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced Health Canada's approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly injectable product. BRAVECTO® QUANTUM is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and for the treatment and control of tick infestations with Ixodes scapularis (black-legged tick), Dermacentor variabilis (American d

    10/2/25 8:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr

    10/1/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Financials

    Live finance-specific insights

    View All

    Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr

    10/1/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    REPAY Reports Second Quarter 2025 Financial Results

    Sequential Improvement in Growth and Strong Free Cash Flow Conversion in Q2 Reiterates 2025 Outlook for Accelerating Growth in Q4 Repurchased 4.8 million shares for $22.6 million during Q2 Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of vertically-integrated payment solutions, today reported financial results for its second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights ($ in millions)   Q2 2024   Q3 2024   Q4 2024   Q1 2025   Q2 2025 Revenue   $ 74.9     $ 79.1     $ 78.3

    8/11/25 4:05:00 PM ET
    $RPAY
    Real Estate

    Conduent Reports Second Quarter 2025 Financial Results

    News from Conduent Key Q2 2025 Highlights Revenue and Adj. Revenue(1): $754MPre-tax Income (Loss): $(38)MAdj. EBITDA Margin(1): 4.9%New Business Signings ACV(2): $150MNet ARR Activity Metric(2) (TTM): $63M FLORHAM PARK, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Conduent Incorporated (NASDAQ:CNDT), a global technology-led business process solutions and services company, today announced its second quarter 2025 financial results. Cliff Skelton, Conduent President and Chief Executive Officer, stated, "Q2 marks another quarter of progress on our journey. We exceeded expectations for Adjusted EBITDA and Adjusted EBITDA margin. Q2 Revenue was in line with guidance and while often affected by se

    8/6/25 8:01:17 AM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer

    PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world's largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providi

    9/22/25 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Conduent Announces Board Leadership Transition

    Harsha V. Agadi Named Chairman, Succeeds Scott Letier Conduent Incorporated (NASDAQ:CNDT), a global technology-driven business solutions and services company, today announced the appointment of Harsha V. Agadi as Chairman of its Board of Directors, effective August 6. He succeeds Scott Letier, who now chairs the Board's Audit Committee. Mr. Agadi joined Conduent's Board in 2025 and previously led its Audit Committee. Mr. Letier has served as a director since 2018 and as Chairman since 2021. These leadership changes are part of the Board's practice of rotating board roles and commitment to strategic governance, as noted in the company's Form 8-K filing on June 25. "We're pleased to wel

    8/6/25 7:45:00 AM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Repay Holdings Corporation

    SC 13G - Repay Holdings Corp (0001720592) (Subject)

    11/14/24 5:17:53 PM ET
    $RPAY
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Conduent Incorporated

    SC 13G/A - CONDUENT Inc (0001677703) (Subject)

    11/14/24 1:28:32 PM ET
    $CNDT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Fiserv Inc.

    SC 13G/A - FISERV INC (0000798354) (Subject)

    11/14/24 1:22:34 PM ET
    $FI
    Real Estate